Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV...
Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Takeda Pharmaceutical Company Limited announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...
Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin. • in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. • in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Takeda has re-filed applications for Nesina (alogliptin) as a monotherapy and alogliptin plus pioglitazone at the FDA following a Complete...